Saegis Receives $3.8 Million From Stanley Medical Research Institute

Saegis Pharmaceuticals, a privately held biopharmaceutical company focused on developing medicines that protect and enhance the function of the human mind, announced that The Stanley Medical Research Institute (SMRI) is providing Saegis with up to $3.8 million to continue funding human clinical trials of SGS518. Saegis is developing SGS518 as a treatment for the cognitive deficit that occurs in schizophrenia. This is the second award that Saegis has received from SMRI for this promising therapeutic clinical development program.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/05-12-2005/0003597069&EDATE=)